跳至主要内容
临床试验/NCT03611400
NCT03611400已完成不适用

The Effect of Probiotic Intake on Intestinal Permeability of Healthy Adults

University of Florida1 个研究点 分布在 1 个国家目标入组 39 人开始时间: 2018年8月22日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
39
试验地点
1
主要终点
Gastroduodenal Permeability

研究概览

简要总结

In this double blind, crossover study participants will take a placebo for 3 weeks each. Gut permeability will be assessed weekly using food-grade sugar molecules. On the second week, participants will take aspirin, which will make their intestine permeable to the sugars. Participants will be asked to provide urine and stool samples to assess gut permeability and microbial communities. No change in permeability to the small sugar probes is anticipated with the probiotic.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Triple (Participant, Investigator, Outcomes Assessor)

盲法说明

The participants, investigators, and anyone else involved with the study will remain blinded for its entirety.

入排标准

年龄范围
21 Years 至 50 Years(Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Healthy individuals, aged 21 to 50 years who have ≥6 stools/week.
  • •Willing to discontinue the use of non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, aspirin, naproxen, or indomethacin, for the full length of the study.
  • •Willing to avoid beer, wine, and cocktails on the day before and the day of the sugar probe tests. The sugar probe tests are visits 2, 3, 4, 6, 7, and
  • •Willing to avoid the use of antidiarrheal or laxative medication on a regular or an "as-needed basis" during the full length of the study.
  • •Willing to provide urine and stool samples during the study collection periods.
  • •Have used aspirin in the past and did not experience adverse effects.
  • •Willing to consume three tablets (325 mg each or 975 mg total) twice within a 9 to 12-hour period. This challenge will be repeated twice during the 14-week study.
  • •Willing to complete online questionnaires, records, and diaries associated with the study and to complete all clinic visits.
  • •Willing to discontinue consumption of fermented foods or probiotics.
  • •Willing to discontinue taking prebiotic, herbal, or high-dose vitamin or mineral supplements that may impact immune function or inflammation during the pre-baseline period and throughout the study protocol.
  • •Willing to avoid high intensity exercises two days prior to and the day of the permeability tests. These tests will be done on six occasions.
  • •Willing and able to consume the probiotic and placebo daily for 3 weeks each.
  • •Willing and able to complete the informed consent form in English.
  • •Willing to provide a social security number to receive study payment.

排除标准

  • •History or current impaired cardiovascular circulation or uncontrolled hypertension, diabetes, bleeding tendencies, kidney, liver or chronic respiratory diseases including asthma, gastrointestinal disorders including heartburn, or any other disease, that by the investigators discretion could interfere with the intestinal barrier function of the subject.
  • •Daily use of NSAIDs in the last 3 months or incidental use in the last 2 weeks prior to screening.
  • •Use of medications in the last 2 weeks prior to the pre-baseline period. This does not include birth control pills or standard multi-vitamin/mineral supplements.
  • •Allergy to aspirin, milk, yeast, or soy.
  • •Known sensitivity to gluten.
  • •Current smokers.
  • •Women who are lactating, know that they are pregnant, or are attempting to get pregnant.
  • •Use of another investigational product within 3 months of the screening visit.

研究组 & 干预措施

Placebo

Placebo Comparator

2 capsules daily for 3 weeks containing the same carrier material and is similar in size, shape and taste to probiotic (group is unknown, double blinded)

干预措施: Placebo (Dietary Supplement)

Probiotic

Experimental

2 capsules daily for 3 weeks, containing 3.8 x 10^9 CFU (colony forming units)/capsule of Lactobacillus rhamnosus strain R011and 0.2 x 10^9 CFU/capsule of L. helveticus strain R0052 (group is unknown, double blinded)

干预措施: Probiotic (Dietary Supplement)

结局指标

主要结局

Gastroduodenal Permeability

时间窗: Week 2 of each intervention

The primary outcome is the difference between the changes in gastroduodenal permeability induced by aspirin challenge with the probiotic versus the placebo. Gastroduodenal permeability will be assessed while on the placebo and probiotic interventions by measuring urinary sucrose in the 0 to 5-hour urine collection of the sugar probe permeability test. Change will be calculated as the urinary sucrose concentration after aspirin challenge (week 2 of each intervention) minus the concentration from the prior week (i.e., 1 wk on intervention with no aspirin challenge).

次要结局

  • Whole Gut Permeability(Weeks 1 and 2 on each intervention)
  • Small Intestinal Permeability(Weeks 1 and 2 on intervention)
  • Colonic Permeability(Weeks 1 and 2 on intervention)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验